Recidivrisiko og varighed af antikoagulerende behandling efter dyb venøs trombose og lungeemboli

Translated title of the contribution: Risk of recurrence and duration of anticoagulant treatment after deep venous thromboembolism and pulmonary embolism

Willemijn Comuth, Anna-Marie Bloch Münster, Thomas Kümler, Maja Hellfritzsch Poulsen, Sanne Bøjet Larsen, Morten Lock Hansen, Erik Lerkevang Grove

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

If anticoagulant therapy is stopped, the risk of recurrence after unprovoked venous thromboembolism is high. After anticoagulant treatment for at least three months, the indication for prolonging therapy should be decided after thorough evaluation of individual risk factors for recurrence and bleeding. Clinical parameters, imaging modalities and D-dimer levels can guide this decision. The lower risk of bleeding on non-vitamin K-antagonist oral anticoagulants compared to warfarin is expected to increase the number of patients on extended treatment, but costs and patients’ preferences should be considered.
Translated title of the contributionRisk of recurrence and duration of anticoagulant treatment after deep venous thromboembolism and pulmonary embolism
Original languageDanish
Article numberV05180345
JournalUgeskrift for Læger
Volume181
Issue number21
Number of pages5
ISSN0041-5782
Publication statusPublished - 11. Feb 2019

Fingerprint

Dive into the research topics of 'Risk of recurrence and duration of anticoagulant treatment after deep venous thromboembolism and pulmonary embolism'. Together they form a unique fingerprint.

Cite this